Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTanta University
About this trial
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥ 18 years.
Both sexes.
Patients with metabolic dysfunction-associated fatty liver disease (MAFLD).
Disqualifiers
History of thyroid disease or treatment (e.g., thyroid nodules, thyroid cancer, hypothyroidism, and hyperthyroidism).
Patients with alcoholic liver disease take more than 40g of alcohol (or four units) per day.
Viral hepatitis.
Pregnant women.
Trial population
This cross-sectional case-control study will be carried out on 150 patients with metabolic dysfunction-associated fatty liver disease (MAFLD) at Tanta University Hospitals for a period from October 2024 to April 2025 after approval from the Institutional Ethical Committee.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Fibroscan
DeviceFibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
Treatment groups
150 Participants
are divided into 2 treatment groupsGroup A: Study group1 intervention
Group B: Control group1 intervention
Trial outcomes
Primary outcomes
1
Level of free triiodothyronine (FT3)
Free triiodothyronine (FT3) will be measured using chemiluminescent immunoassay analysis.
Time frame
After the sample is taken (up to 5 minutes)Secondary outcomes
1
Level of free thyroxine (FT4)
Free thyroxine (FT4) will be measured using chemiluminescent immunoassay analysis.
Time frame
After the sample is taken (up to 5 minutes)2
Level of thyroid stimulating hormone
Thyroid stimulating hormone will be measured using chemiluminescent immunoassay analysis.
Time frame
After the sample is taken (up to 5 minutes)3
Relation between gender and thyroid function
Relation between gender and thyroid function will be assessed.
Time frame
After the sample is taken (up to 5 minutes)4
Correlation between metabolic data and thyroid function tests
Correlation between metabolic data and thyroid function tests will be assessed.
Time frame
After the sample is taken (up to 5 minutes)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov